fosamprenavir/ritonavir (1400mg/100mg BID)

TERMINATED · PHASE3 · HIV-1

Incomplete data

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.